Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-01-27

FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Stribild, updating the product labeling for this fixed-dose HIV-1 regimen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)

Snippet

SUPPL AP for STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE)